Skip to content
PaperFren

Oncology outcomes

How does luteolin slow diffuse large B-cell lymphoma?

Zhan XZ, Bo YW, Zhang Y, et al. · Frontiers in pharmacology · 2025

Open access · cc by · source: Europe PMC

The flavonoid luteolin inhibited DLBCL cell growth (IC50 ~11–12 μM), drove G2/M arrest and apoptosis, and shrank U2932 xenografts while lowering p-JAK2/p-STAT3.

Save to libraryView originalAsk PaperFrenStudy view

Study at a glance

Design
Animal / in-vitro — DLBCL cell lines (U2932, OCI-LY10) plus U2932 xenograft nude mice (4 groups × n=5) and JAK2 docking/MD.
N
N=20 · In vivo n=5 mice × 4 dose groups (0, 12.5, 25, 50 mg/kg); in vitro two human DLBCL lines.
Population
Human DLBCL cell lines U2932 and OCI-LY10 and U2932-bearing nude mice.
Outcome
Proliferation IC50, apoptosis, G2/M arrest, xenograft growth, and p-JAK2/p-STAT3 vs total JAK2/STAT3.

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

IC50 10.91 μM (U2932) and 12.03 μM (OCI-LY10). Apoptosis at 20 μM reached ~54% (U2932) and ~67% (OCI-LY10). G2/M fractions rose dose-dependently. Xenograft volume/weight fell without much body-weight loss; p-JAK2 and p-STAT3 fell while total JAK2/STAT3 stayed flat; Bax/cleaved caspase-3/PARP1 rose.

Methodology

CCK-8, Annexin V, and cell-cycle assays on U2932/OCI-LY10 at 0–20 μM; nude mice with U2932 tumors got 12.5/25/50 mg/kg luteolin IP twice daily for 14 days vs saline; Western blots and JAK2 docking/MD.

Limitations

No human trial; two cell lines and n=5/group mice; JAK2 binding is computational; clinical DLBCL already has R-CHOP, so luteolin is a candidate mechanism, not a proven therapy.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Related papers in this topic

Same topic cluster — not a recommendation engine.